

### AMENDMENTS TO THE CLAIMS

1. (Original) A method of protecting a patient from one or more treatments that trigger apoptosis comprising administering to the patient a composition comprising a pharmaceutically acceptable amount of a PTEN inhibitor selected from the group consisting of compounds I-XIV.

2. (Original) The method of claims 1, wherein the treatment is a cancer treatment.

3. (Original) The method of claim 2, wherein the PTEN inhibitor is administered prior to, together with, or after a treatment for the cancer.

4. (Currently Amended) The method of claim {0006} 2, wherein the treatment is chemotherapy or radiation therapy.

5. (Original) A method of treating a patient suffering from damage to normal tissue attributable to stress, comprising administering to the patient a composition comprising a pharmaceutically acceptable amount of a PTEN inhibitor selected from the group consisting of compounds I-XIV.

6. (Currently Amended) The method of claim {0007} 5, wherein the PTEN inhibitor is administered prior to, together with, or after a treatment for a disease suffered by the patient.

7. (Original) A method of sensitizing cancer cells to an inhibitor of the PI3 kinase pathway comprising administering to a patient in need of such treatment a PTEN inhibitor selected from the group consisting of compounds I-XIV.

8. (Currently Amended) A method of treating apoptosis associated with a medical procedure comprising administering to a patient in need of such treatment a PTEN inhibitor ~~PTEN-inhibitor~~ selected from the group consisting of compounds I-XIV.

9. (Original) A method of protecting a patient from radiation or chemical exposure comprising administering to the patient a composition comprising a pharmaceutically acceptable amount of a PTEN inhibitor selected from the group consisting of compounds I-XIV.

10. (Original) The method of claim 9 wherein the PTEN inhibitor is administered prior to, together with, or after the said radiation or chemical exposure.

11. (Original) A method of sensitizing cancer stem cells by exposing said cells to a PTEN inhibitor selected from the group consisting of compounds I-XIV.

12. (Original) The method of claim 9 wherein the PTEN inhibitor is administered prior to, together with, or after a treatment for a disease suffered by the patient.